Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol
| Autor: | Raita Araki, Ryosei Nishimura, Anri Inaki, Hiroshi Wakabayashi, Yasuhito Imai, Yoshikazu Kuribayashi, Kenichi Yoshimura, Toshinori Murayama, Seigo Kinuya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Asia Oceania Journal of Nuclear Medicine and Biology, Vol 6, Iss 2, Pp 161-166 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2322-5718 2322-5726 |
| DOI: | 10.22038/aojnmb.2018.29845.1203 |
| Popis: | Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand hematopoietic stem cell transplantation.Methods: Patients with high-risk neuroblastoma will be enrolled in this study. A totalof 8 patients will be registered. Patients will receive 666 MBq/kg of 131I-MIBG andafter safety evaluation will undergo high-dose chemotherapy and hematopoietic stemcell transplantation. Autologous and allogeneic stem cell sources will be accepted.After engraftment or 28 days after hematopoietic stem cell transplantation, the safetyand response will be evaluated.Conclusion: This is the first prospective study of 131I-MIBG with high-dosechemotherapy and hematopoietic stem cell transplantation in Japan. The results willbe the basis of a future nationwide clinical trial. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|